Form 4: Apellis Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, sold 825 shares of common stock to cover tax obligations related to released Restricted Stock Units.

Summary

• Nur Nicholson, the Chief Technical Officer of Apellis Pharmaceuticals, sold 825 shares of the company's common stock on January 29, 2025.
• The sale was executed at a price of $29.5236 per share.
• This transaction was to cover tax withholding obligations related to Restricted Stock Units that vested on January 28, 2025.
• Following the transaction, Nicholson directly owns 83,664 shares of Apellis Pharmaceuticals stock.

Sentiment

Score: 5

Explanation: This is a neutral event, a routine transaction for an executive to cover tax obligations. It doesn't indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales by executives.
• The volume of shares sold is relatively small compared to the total holdings of the executive, which is typical for these types of transactions.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a small transaction by an executive to cover tax obligations.

Key Dates

Keywords

Apellis Pharmaceuticals, insider trading, stock sale, Nur Nicholson, executive, tax obligations, restricted stock units, APLS